At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 58 enrolled
Drug / intervention
Xalatan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ocular Surface Changes With Topical Prostaglandin Analog Therapy
In Brief
A Phase 4 clinical trial evaluating Xalatan and Travatan Z for Glaucoma. Completed, enrolled 58 participants across 1 site.
Detailed Summary
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
Study Details
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionJan 2011
Study CompletionFeb 2011
TodayJul 2026
First PostedNov 26, 2008
Enrollment StartNov 1, 2008
Primary CompletionJan 1, 2011
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.6 years ago
Interventions
Xalatandrug
one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Zdrug
one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime